This self-paced course introduces healthcare workers to new TB medicines such as bedaquiline and delamanid, and new regimens such as the 9 month regimen, and the responsible use of them, for the treatment of multi-drug resistant TB (MDR-TB).
To join this course:
Introduction to Using New TB Medicines & Regimens
This course is now open! Follow the instructions above to join and start learning.
The goal of this course is to introduce healthcare workers to new TB medicines such as bedaquiline and delamanid, and new regimens such as the 9 month regimen, and the responsible use of them, for the treatment of multidrug resistant TB (MDR-TB).
This course is intended for use by physicians, nurses, pharmacists and all healthcare workers who are currently engaged in the management of MDR-TB patients. Workers in National TB Control Programs, Ministries of Health and NGOs who are looking to introduce new TB medicines and regimens in their countries will also greatly benefit from this course.
The information in this course has been developed based on publicly available resources from the World Health Organization (WHO) and other sources. It has been taught via in-person workshops to hundreds of healthcare workers in a total of five countries. Now this information is available to you at no cost.
This course was developed by the USAID-funded Systems for Improving Access to Pharmaceuticals and Services (SIAPS) Program.
You can choose to review all the modules in this course or simply pick the ones that are most relevant to your practice setting. Whether you are new to the topics and want to view the entire course in sequential order, or if you a need a refresher or want to view a specific topic or resource, you can do so. You do not have to complete all the modules at once; go at your own pace and learn in your free time as desired.
Begin exploring this course by clicking on the Course Outline tab to select learning modules/units and track your progress. The FAQ tab provides answers to common questions and tips for using this course.